NCT06736704 2026-03-13
SNV4818 in Participants With Advanced Solid Tumors
Pikavation Therapeutics, Inc.
Phase 1/2 Recruiting
Clinical Trials
94 trialsNCT06596473 2026-03-05
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07387068 2026-03-04
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Genmab
Phase 1 Recruiting
NCT07446816 2026-03-03
A Clinical Study Evaluating the Preliminary Anti-tumor Efficacy and Safety of Hemay181
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1 Recruiting
NCT05083481 2026-02-27
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
Phase 1/2 Recruiting
NCT05067283 2026-02-12
KANDLELIT-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT07328217 2026-02-11
A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors
Dizal Pharmaceuticals
Phase 1/2 Recruiting
NCT05620017 2026-02-09
Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection
Bio-Thera Solutions
Phase 1 Recruiting
NCT06480552 2026-02-05
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Recruiting
NCT07359066 2026-02-05
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase 1/2 Recruiting
NCT06697197 2026-02-03
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT07266428 2026-02-03
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Ottimo Pharma Limited
Phase 1/2 Recruiting
NCT04626635 2026-02-02
COMBINE-EGFR-1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT07215637 2026-02-02
Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Chong Kun Dang Pharmaceutical
Phase 1 Recruiting
NCT07377591 2026-01-30
A Study of HDM2006 in Patients With Advanced Solid Tumor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06792552 2026-01-29
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NextCure, Inc.
Phase 1 Recruiting
NCT05867420 2026-01-27
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
AskGene Pharma, Inc.
Phase 1/2 Recruiting
NCT07042100 2026-01-22
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
Sun Pharma Advanced Research Company Limited
Phase 1 Recruiting
NCT07093970 2026-01-22
A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
Lepu Biopharma Co., Ltd.
Phase 1/2 Recruiting
NCT06770569 2026-01-21
Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
Shandong Suncadia Medicine Co., Ltd.
Phase 1 Recruiting
NCT07356453 2026-01-21
A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.
FoRx Therapeutics AG
Phase 1 Recruiting
NCT06927570 2026-01-16
A Study of HS-20122 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT07186452 2026-01-16
Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT07231458 2026-01-16
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
Abalos Therapeutics GmbH
Phase 1 Recruiting
NCT07349160 2026-01-16
Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1 Recruiting
NCT07253116 2026-01-14
A Phase I/II Clinical Study of WJ22096 Tablets in Patients With Advanced Tumors
Nanjing Jingao biomidical technology Co. Ltd.
Phase 1/2 Recruiting
NCT06741644 2026-01-09
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2 Recruiting
NCT06990464 2026-01-08
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
Shanghai Institute Of Biological Products
Phase 1 Recruiting
NCT07131202 2026-01-08
A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors
Suzhou Forlong Biotechnology Co., Ltd
Phase 1/2 Recruiting
NCT07252414 2026-01-05
GenSci143 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05277168 2026-01-02
A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS
Jiangsu HengRui Medicine Co., Ltd.
Phase 1/2 Recruiting
NCT06384352 2026-01-02
A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1 Recruiting
NCT07310134 2026-01-02
Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors
Nanjing Zenshine Pharmaceuticals
Phase 1 Recruiting
NCT06882135 2025-12-29
HW071021 Monotherapy in Patients With Advanced Solid Tumors
Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
Phase 1 Recruiting
NCT07230977 2025-12-24
GenSci139 in Patients With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT07251166 2025-12-24
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of GenSci140 in Participants With Advanced Solid Tumors
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06459973 2025-12-23
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT07266285 2025-12-17
BTM-3566 in Advanced Solid Tumors
Bantam Pharmaceuticals
Phase 1 Recruiting
NCT07285395 2025-12-16
AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study
The Affiliated Hospital of Xuzhou Medical University
Phase 1 Recruiting
NCT06736327 2025-12-08
A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT06428331 2025-12-05
A Study of SKB518 in Patients With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT06826040 2025-12-05
SKB445 for Injection in Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT06703177 2025-12-03
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1/2 Recruiting
NCT06840821 2025-12-02
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
Mainline Biosciences (Shanghai) Co., Ltd
Phase 1/2 Recruiting
NCT07208136 2025-12-01
A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors
Jemincare
Phase 1 Recruiting
NCT07241936 2025-11-28
A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Recruiting
NCT06238401 2025-11-24
An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1 Recruiting
NCT05367635 2025-11-17
A Study of SKB315 in Patients With Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1 Recruiting
NCT06618651 2025-11-17
A Study of SHR-3821 Injection in Subjects With Advanced Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 1 Recruiting
NCT07019779 2025-11-17
Study of CM518D1 in Patients With Advanced Solid Tumors
Keymed Biosciences Co.Ltd
Phase 1/2 Recruiting